Heartflow (NASDAQ:HTFL) Stock Price Down 7.4% Following Insider Selling

Heartflow, Inc. (NASDAQ:HTFL) shares dropped 7.4% during trading on Tuesday following insider selling activity. The stock traded as low as $26.73 and last traded at $27.13. Approximately 1,594,640 shares changed hands during mid-day trading, an increase of 15% from the average daily volume of 1,386,446 shares. The stock had previously closed at $29.29.

Specifically, CEO John C.M. Farquhar sold 22,562 shares of the firm’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $27.46, for a total value of $619,552.52. Following the completion of the transaction, the chief executive officer owned 591,656 shares in the company, valued at $16,246,873.76. This trade represents a 3.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Julie A. Cullivan sold 8,000 shares of the company’s stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $27.32, for a total transaction of $218,560.00. Following the completion of the transaction, the director owned 36,413 shares of the company’s stock, valued at approximately $994,803.16. This trade represents a 18.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In other news, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $28.05, for a total transaction of $56,100,000.00. Following the transaction, the insider owned 10,448,158 shares in the company, valued at approximately $293,070,831.90. The trade was a 16.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Wall Street Analyst Weigh In

HTFL has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Stifel Nicolaus lifted their price objective on Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. increased their target price on shares of Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Wells Fargo & Company assumed coverage on shares of Heartflow in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 price target on the stock. Finally, Canaccord Genuity Group lifted their target price on shares of Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $38.50.

More Heartflow News

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Analyst upgrades and bullish price-target revisions remain on the tape (Wells Fargo started coverage with an “overweight”; Canaccord, JPMorgan and Stifel have raised targets toward ~$38–$40), supporting medium-term upside expectations.
• Neutral Sentiment: Several smaller institutional investors added positions in recent quarters — a modest vote of confidence but not large enough to offset other flows on its own.
• Negative Sentiment: CEO John C.M. Farquhar sold 22,562 shares at an average $27.46 (~$619.6k). Insider sales by the CEO can signal liquidity-taking and often weigh on sentiment. CEO Form 4
• Negative Sentiment: Director Julie Cullivan sold 8,000 shares at about $27.32 (~$218.6k), reducing her stake ~18%, which adds to negative insider-selling optics. Director Form 4
• Negative Sentiment: Reported large shareholder sell-off (headline noting ~$56.1M in stock sold) increases supply and likely pressured the share price. Major Shareholder Sale
• Negative Sentiment: Short interest surged in January to ~4.95M shares (up ~42% from mid‑January), representing ~5.8% of shares outstanding and ~5.9 days-to-cover — a material rise that can amplify downward moves as traders increase bearish positioning.

Heartflow Trading Down 6.8%

The company has a market cap of $2.32 billion and a P/E ratio of -15.08. The firm’s 50-day simple moving average is $30.26.

Hedge Funds Weigh In On Heartflow

Institutional investors and hedge funds have recently made changes to their positions in the stock. TFC Financial Management Inc. bought a new stake in Heartflow in the 3rd quarter valued at about $40,000. Legal & General Group Plc acquired a new stake in Heartflow in the third quarter valued at approximately $59,000. Strs Ohio acquired a new position in shares of Heartflow during the fourth quarter worth approximately $99,000. Staley Capital Advisers Inc. bought a new position in shares of Heartflow in the 4th quarter worth $204,000. Finally, Connable Office Inc. acquired a new stake in Heartflow in the 4th quarter valued at $220,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.